PMID- 35339478
OWN - NLM
STAT- MEDLINE
DCOM- 20220426
LR  - 20220426
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 923
DP  - 2022 May 15
TI  - A promising antifibrotic drug, pyridoxamine attenuates thioacetamide-induced 
      liver fibrosis by combating oxidative stress, advanced glycation end products, 
      and balancing matrix metalloproteinases.
PG  - 174910
LID - S0014-2999(22)00171-6 [pii]
LID - 10.1016/j.ejphar.2022.174910 [doi]
AB  - Liver fibrosis is a common chronic hepatic disease. This study was done to 
      examine the effect of pyridoxamine against thioacetamide-induced hepatic 
      fibrosis. Animals were divided into four groups (1) control group; (2) 
      Thioacetamide group (200 mg/kg, i.p.) twice a week for eight weeks; (3) 
      Pyridoxamine-treated group treated with pyridoxamine (100 mg/kg/day, i.p.) for 
      eight weeks; (4) Thioacetamide and pyridoxamine group, in which pyridoxamine was 
      given (100 mg/kg/day, i.p.) during thioacetamide injections. Thioacetamide 
      treatment resulted in hepatic dysfunction manifested by increased serum levels of 
      bilirubin, gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), and 
      aspartate aminotransferase (AST). Oxidative stress was noted by increased hepatic 
      lipid peroxidation and decreased glutathione (GSH). Increased concentrations of 
      total nitrite/nitrate, advanced glycation end products (AGEs), monocyte 
      chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha), transforming 
      growth factor-beta (TGF-beta), matrix metalloproteinases (MMP-2&9) and tissue inhibitor 
      of metalloproteinase-1 (TIMP-1) were noticed in hepatic tissues. Immunostaining 
      sections also revealed overexpression of MMP-2, MMP-9 and collagen IV. Liver 
      fibrosis was confirmed by severe histopathological changes. Pyridoxamine improved 
      the assessed parameters. Moreover, histopathological and immunohistological 
      studies supported the ability of pyridoxamine to reduce liver fibrosis. The 
      findings of the present study provide evidence that pyridoxamine is a novel 
      target for the treatment of liver fibrosis.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Alshanwani, Aliah R
AU  - Alshanwani AR
AD  - Physiology Department, College of Medicine & King Khalid University Hospital, 
      King Saud University, Riyadh, Saudi Arabia.
FAU - Hagar, Hanan
AU  - Hagar H
AD  - Physiology Department, College of Medicine & King Khalid University Hospital, 
      King Saud University, Riyadh, Saudi Arabia. Electronic address: 
      hhagar@ksu.edu.sa.
FAU - Shaheen, Sameerah
AU  - Shaheen S
AD  - Anatomy Department and Stem Cell Unit, College of Medicine, King Saud University, 
      Riyadh, Saudi Arabia.
FAU - Alhusaini, Ahlam M
AU  - Alhusaini AM
AD  - Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud 
      University, Riyadh, Saudi Arabia.
FAU - Arafah, Maha M
AU  - Arafah MM
AD  - Pathology Department, College of Medicine, King Saud University, Riyadh, Saudi 
      Arabia.
FAU - Faddah, Laila M
AU  - Faddah LM
AD  - Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud 
      University, Riyadh, Saudi Arabia.
FAU - Alharbi, Fatima Mb
AU  - Alharbi FM
AD  - Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi 
      Arabia.
FAU - Sharma, Arun K
AU  - Sharma AK
AD  - Pharmacology Department, Amity Institute of Pharmacy, Amity University, Gurugram, 
      Haryana, 122413, India.
FAU - Fayed, Amel
AU  - Fayed A
AD  - Clinical Sciences Department, College of Medicine, Princess Nourah Bint 
      Abdulrahman University, Saudi Arabia. Electronic address: aafayed@pnu.edu.
FAU - Badr, Amira M
AU  - Badr AM
AD  - Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud 
      University, Riyadh, Saudi Arabia; Pharmacology and Toxicology Department, College 
      of Pharmacy, Ain Shams University, Cairo, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20220323
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 075T165X8M (Thioacetamide)
RN  - 6466NM3W93 (Pyridoxamine)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
SB  - IM
MH  - Animals
MH  - Glycation End Products, Advanced/pharmacology
MH  - Liver
MH  - Liver Cirrhosis/chemically induced/drug therapy/pathology
MH  - *Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinases/metabolism
MH  - Oxidative Stress
MH  - Pyridoxamine/metabolism/pharmacology/therapeutic use
MH  - *Thioacetamide/pharmacology
MH  - Tissue Inhibitor of Metalloproteinase-1/metabolism
OTO - NOTNLM
OT  - Advanced glycation end products
OT  - Liver fibrosis
OT  - Matrix metalloproteinases
OT  - Pyridoxamine
OT  - Tissue inhibitor of matrix metalloproteinase-1
OT  - Transforming growth factor-beta
EDAT- 2022/03/28 06:00
MHDA- 2022/04/27 06:00
CRDT- 2022/03/27 20:20
PHST- 2022/03/06 00:00 [received]
PHST- 2022/03/18 00:00 [accepted]
PHST- 2022/03/28 06:00 [pubmed]
PHST- 2022/04/27 06:00 [medline]
PHST- 2022/03/27 20:20 [entrez]
AID - S0014-2999(22)00171-6 [pii]
AID - 10.1016/j.ejphar.2022.174910 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2022 May 15;923:174910. doi: 10.1016/j.ejphar.2022.174910. Epub 
      2022 Mar 23.